Sudhir Manda

626 total citations
26 papers, 174 citations indexed

About

Sudhir Manda is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Sudhir Manda has authored 26 papers receiving a total of 174 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 10 papers in Oncology and 9 papers in Genetics. Recurrent topics in Sudhir Manda's work include Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Sudhir Manda is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (7 papers) and Lymphoma Diagnosis and Treatment (6 papers). Sudhir Manda collaborates with scholars based in United States, Czechia and Canada. Sudhir Manda's co-authors include Spencer James, Seby John, Daniel O. Persky, Michael C. Churnetski, Stephen M. Amrock, Max J. Gordon, Stephen E. Spurgeon, Joseph Gibbons, Jonathon B. Cohen and Afshin Dowlati and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Sudhir Manda

25 papers receiving 172 citations

Peers

Sudhir Manda

GENET

PFM

HEMAT

ONCOL

Melanie Oates United Kingdom

Nour Abuhadra United States

Aytug Kizilors United Kingdom

Dipti Pawaskar United States

Pierre–Olivier Schischmanoff France

Liye Zhong China

Eugenio Lucia Italy

Nicla Manes Italy

Vassilios Aslanis United States

A. Megan Cornelison United States

Melanie Oates United Kingdom

Sudhir Manda

69 ×0.9

GENET

43 ×0.7

PFM

17 ×0.3

HEMAT

130 ×3.3

84 ×2.3

ONCOL

Citations per year, relative to Sudhir Manda Sudhir Manda (= 1×) peers Melanie Oates

Countries citing papers authored by Sudhir Manda

Since Specialization

Citations

This map shows the geographic impact of Sudhir Manda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sudhir Manda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sudhir Manda more than expected).

Fields of papers citing papers by Sudhir Manda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sudhir Manda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sudhir Manda. The network helps show where Sudhir Manda may publish in the future.

Co-authorship network of co-authors of Sudhir Manda

This figure shows the co-authorship network connecting the top 25 collaborators of Sudhir Manda. A scholar is included among the top collaborators of Sudhir Manda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sudhir Manda. Sudhir Manda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2024). A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia. Hematological Oncology. 42(3). e3274–e3274. 6 indexed citations

Christenson, Eric S., Daruka Mahadevan, Syed Mohammad Ali Kazmi, et al.. (2024). A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 2538–2538. 2 indexed citations

Thaker, Nikhil G., Adam P. Dicker, Arturo Loaiza‐Bonilla, et al.. (2024). The Role of Artificial Intelligence in Early Cancer Detection: A Primer on Artificial Intelligence. 1(2). 82–90. 1 indexed citations

Thaker, Nikhil G., Adam P. Dicker, Arturo Loaiza‐Bonilla, et al.. (2024). The Role of Artificial Intelligence in Early Cancer Detection: Exploring Early Clinical Applications. 1(2). 91–105. 1 indexed citations

Rifkin, Robert M., Saulius Girnius, Stephen J. Noga, et al.. (2023). In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management. Blood Cancer Journal. 13(1). 147–147. 2 indexed citations

Paul, Barry, Jiří Minařík, Francesca Cottini, et al.. (2023). Safety and Tolerability of Magrolimab Combinations in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Safety Run-in Results from a Phase 2 Study. Blood. 142(Supplement 1). 3383–3383. 2 indexed citations

Manda, Sudhir, Habte Yimer, Ruemu Birhiray, et al.. (2022). MM-253 Efficacy, Safety, and Quality of Life (QoL) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) After In-Class Transition (iCT) From Parenteral Bortezomib-Based Induction Therapy to All-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd): Data From the Phase 4, Community-Based US MM-6 Study (Fully Accrued Cohort). Clinical Lymphoma Myeloma & Leukemia. 22. S416–S417. 1 indexed citations

Manda, Sudhir, Bertrand Anz, Christopher B. Benton, et al.. (2021). Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia. Blood. 138(Supplement 1). 1265–1265. 3 indexed citations

Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2021). Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study. Blood. 138(Supplement 1). 3725–3725. 1 indexed citations

10.

Manda, Sudhir, Habte Yimer, Stephen J. Noga, et al.. (2020). Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib. Clinical Lymphoma Myeloma & Leukemia. 20(11). e910–e925. 11 indexed citations

11.

Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2020). Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study. Blood. 136(Supplement 1). 4–5. 2 indexed citations

12.

Shah, Nirav N., Leslie Popplewell, Charalambos Andreadis, et al.. (2020). Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma. Blood. 136(Supplement 1). 29–30. 8 indexed citations

13.

Noga, Stephen J., Robert M. Rifkin, Sudhir Manda, et al.. (2019). Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (btz) to Ixazomib: The US MM-6 Community-Based Study. Blood. 134(Supplement_1). 3168–3168. 4 indexed citations

14.

Sharman, Jeff P., David Andorsky, Jason M. Melear, et al.. (2019). Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study. Blood. 134(Supplement_1). 3042–3042. 4 indexed citations

15.

Gordon, Max J., Michael C. Churnetski, Adam S. Kittai, et al.. (2018). Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 124(15). 3192–3200. 53 indexed citations

16.

Manda, Sudhir, et al.. (2014). Impact of Comorbidities on Treatment Outcomes in Chronic Lymphocytic Leukemia: A Retrospective Analysis. Blood. 124(21). 1312–1312. 15 indexed citations

17.

John, Seby, et al.. (2011). Cocaine-Induced Thrombotic Vasculopathy. The American Journal of the Medical Sciences. 342(6). 524–526. 16 indexed citations

18.

Nock, Charles, Joanna M. Brell, Joseph A. Bokar, et al.. (2009). A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Investigational New Drugs. 29(1). 126–130. 17 indexed citations

19.

Thota, Swapna, et al.. (2009). A Rare Case of Primary Ovarian Lymphoma in Patients With Rheumatoid Arthritis: Can We Attribute This to Tumor Necrosis Factor Inhibitors?. 2(2). 121–123. 1 indexed citations

20.

Dowlati, Afshin, et al.. (2008). Multi-Institutional Phase I Trials of Anticancer Agents. Journal of Clinical Oncology. 26(12). 1926–1931. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact